FDA's final PDURS guidance establishes a clear pathway for drug-software combinations to deliver and demonstrate meaningful clinical benefits.
FDA's final guidance confirms that clinically meaningful benefits from software used alongside a prescription drug can be reflected directly in the drug's labeling. It also provides greater regulatory clarity for standalone software, creating new opportunities for pharmaceutical companies to enhance treatment efficacy, differentiate medicines, and address unmet clinical needs.
